CANY
CARM

Caxton Associates (New York)’s Carisma Therapeutics CARM Stock Holding History

Caxton Associates (New York)’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,240
Closed -$392K – 460
2021
Q2 		$392K Buy
+4,240
New +$270K 0.04% 238

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Caxton Associates (New York)'s CARM Position: Q3 2021 in Review

Caxton Associates (New York) sold out of Carisma Therapeutics (CARM) in Q3 2021, closing a stake of 4,240 shares — an estimated $392K sold.

Caxton Associates (New York) first reported a position in CARM in Q2 2021 and held it in 1 quarter. The position peaked at $392K in Q2 2021. 103 funds tracked by Wall St. Rank hold CARM as of Q3 2021.

  • Caxton Associates (New York) reported no remaining Carisma Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Caxton Associates (New York) sold 4,240 Carisma Therapeutics shares in Q3 2021, an estimated $392K.
  • Caxton Associates (New York) first reported a position in Carisma Therapeutics in Q2 2021 and held it in 1 quarter.
  • Caxton Associates (New York)'s Carisma Therapeutics position peaked at $392K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2021.

Based on Caxton Associates (New York)'s 13F filing for Q3 2021, filed 15 Nov 2021.